Episode 9 - Cancer Immunotherapy

Show notes:
In the show, The BioBusters professors, Dr. A and Dr. C, discuss the science behind the 2018 Nobel Prize in Physiology or Medicine. The BioBusters Docs discuss checkpoint control in immune responses, as well as activating and inhibitory receptors on T cells. The Docs discuss the various FDA approved checkpoint inhibitor drugs and the cancers they treat. Keep the discussion and comments going on the iTunes review section, or feel free to e-mail the podcast with future show ideas and thoughts on the current show.
Music by Bahaa Naamani
Email us at thebiobusters@gmail.com
 
References:
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Fouser, L., Carter, L., Ling, V., Bowman, M.R., Carreno, B.M., Collins, M., Wood, C.R. & Honjo, T. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7), 1027–1034.
Hodi, F.S., Mihm, M.C., Soiffer, R.J., Haluska, F.G., Butler, M., Seiden, M.V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., Padera, R., Jaklitsch, M.T., Shankar, S., Chen, T.C., Korman, A., Allison, J.P. & Dranoff, G. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA, 100(8), 4712-4717
https://www.nobelprize.org/prizes/medicine/2018/press-release/
https://blog.dana-farber.org/insight/2015/09/what-is-a-checkpoint-inhibitor/
https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html
https://www.science.org.au/curious/people-medicine/releasing-immune-systems-brakes-fight-cancer
https://www.wired.com/story/cancer-immunotherapy-has-arrived-but-not-for-everyone/
https://www.sciencedaily.com/releases/2018/10/181009102517.htm